EAGAN, Minn. – Prime Therapeutics LLC (Prime) released the following statement on the U.S. Food and Drug Administration’s (FDA) recent biosimilar announcement:

“Prime strongly supports the Administration’s efforts to bring biosimilar drugs to market faster – and at a lower cost – than ever before. Through this announcement, Health and Human Services (HHS) and the Food and Drug Administration (FDA) are making interchangeability a reality, finally enabling pharmacists to substitute approved biosimilars for brand biologics, expanding the options patient have and helping to reduce prescription drug costs. With unnecessary barriers lifted, the pathway to widespread biosimilar adoption – and meaningful savings for patients – is now within reach. 

“Prime has been a consistent leader in biosimilar adoption and making them available at an affordable cost to our patients for some of the most complex medical conditions. Our evidence-based approaches to driving uptake of biosimilars as an alternative to costly brand biologics have saved more than $2 billion for our clients to date, which translates to deeper savings for the patients we collectively serve.¹

“We encourage the Administration to keep pushing forward for full biosimilar interchangeability and for Congress to pass the Biosimilar Red Tape Elimination Act to streamline development of more biosimilars, enhance regulatory predictability and accelerate patient access to lower-cost biologics.”

References

1. Internal Prime data